Low-Dose Buspirone as Adjunct for Severe GERD
Buspirone is not recommended as adjunct therapy for severe GERD based on current AGA guidelines, which do not include it among evidence-based adjunctive pharmacotherapy options. 1
Guideline-Recommended Adjunctive Therapies for Severe GERD
The 2022 AGA Clinical Practice Update explicitly outlines a personalized approach to adjunctive pharmacotherapy for GERD, and buspirone is notably absent from these recommendations. 1
The guideline-endorsed adjunctive agents include:
- Alginate antacids for breakthrough symptoms, particularly post-prandial and nighttime symptoms, especially in patients with hiatal hernia 1
- H2 receptor antagonists (H2RAs) for nocturnal breakthrough symptoms (though limited by tachyphylaxis with frequent use) 2, 1
- Baclofen (a GABA-B agonist) for regurgitation or belch-predominant symptoms, though often limited by CNS and GI side effects 1
- Prokinetics for coexistent gastroparesis (not useful for GERD alone) 1
The guidelines emphasize personalizing adjunctive pharmacotherapy to the GERD phenotype rather than empiric use of agents. 1
Why Buspirone Is Not Recommended
Lack of Guideline Support
The most recent and authoritative AGA guidelines (2022-2023) make no mention of buspirone for GERD management, despite comprehensive discussion of adjunctive therapies. 2, 1
Limited and Contradictory Research Evidence
While one small Iranian study (2020) suggested buccal buspirone 10 mg/day plus omeprazole improved GERD symptoms compared to omeprazole alone, this single study has significant limitations and has not been incorporated into clinical guidelines. 3
More importantly, a large multi-center randomized controlled trial (2023) specifically evaluated buspirone for gastroparesis-related symptoms including early satiety and postprandial fullness, finding no benefit for the primary outcome. 4 This trial found buspirone performed no better than placebo for early satiety/postprandial fullness (mean difference: -0.11, p = 0.69). 4
FDA-Approved Indications
The FDA label for buspirone indicates approval only for anxiety disorders, with no mention of GERD or gastrointestinal indications. 5 Using buspirone for GERD would be off-label without supporting guideline evidence.
Mechanism and Context
One study in systemic sclerosis patients showed buspirone increased lower esophageal sphincter (LES) pressure, but this was in a highly specific population with scleroderma-related esophageal dysfunction, not typical GERD. 6 This mechanism has not translated to benefit in general GERD populations.
Recommended Approach for Severe GERD
For patients with severe GERD (Los Angeles C or D esophagitis, bi-positional reflux, extreme acid exposure with AET >12%, or large hiatal hernia), the evidence-based approach includes: 1
Indefinite long-term PPI therapy at the lowest effective dose (typically requiring at least single-dose daily PPI) 1
PPI optimization: ensuring adequate timing, considering escalation to twice-daily dosing, or switching to a different PPI 1
Phenotype-specific adjunctive therapy as outlined above (alginates, H2RAs, baclofen) 1
Pharmacologic neuromodulation (low-dose antidepressants) and/or behavioral interventions (CBT, hypnotherapy, diaphragmatic breathing) for patients with esophageal hypervigilance, reflux hypersensitivity, or functional overlay 1
Consideration of invasive anti-reflux procedures (laparoscopic fundoplication, magnetic sphincter augmentation, or transoral incisionless fundoplication) in carefully selected patients with proven GERD who have inadequate response to optimized medical therapy 1
Clinical Pitfalls
Do not empirically add buspirone to GERD regimens without guideline support or strong evidence. The 2022 AGA guidelines specifically warn against empiric use of adjunctive agents and emphasize phenotype-directed therapy. 1
If considering neuromodulation for GERD with functional overlay or hypersensitivity, use guideline-recommended approaches (low-dose antidepressants, behavioral therapy) rather than buspirone. 1